Papaverine Morphine Codeine Molecular weight (daltons)375.8375.8371.9% Protein binding9020–357% Excreted unchanged in urine<110<5Volume of distribution (L/kg)0.99–1.52 3–53–4half-life – normal/ESRD (hrs)1.2–2.2/– 2–3/ Un-changed2.5–4/–
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function
10 to 20     : 0.4–0.75 mL every 6–8 hours
<10           : 0.25–0.5 mL every 6–8 hours. Avoid if possible
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in GFR <10 mL/min
HD                     :Unlikely to be dialysed. Dose as in GFR <10 mL/min
HDF/high flux   :Unlikely to be dialysed. Dose as in GFR <10 mL/min
CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Anti-arrhythmics: delayed absorption of mexiletine
Antidepressants: possible CNS excitation or depression with MAOIs – avoid concomitant use; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics
Antivirals: concentration possibly increased with ritonavirSodium oxybate: enhanced effect of sodium oxybate – avoid concomitant use
ADMINISTRATION
Reconstition
–
Route
SC, IM, IV
Rate of Administration
IV bolus or continuous infusion (1 mg/mL)
Comments
–
OTHER INFORMATION
As with all opiates, use with extreme caution in patients with impaired renal functionMay cause excessive sedation and respiratory depressionPapaveretum 15.4 mg =1 mL ≡ 10 mg morphine.